Tolerion Tolerion is a biopharmaceutical company with a product portfolio built around its antigen-specific immune tolerance induction platform. | ![]() Spexis Spexis (formerly known as Polyphor) is a bioengineering company that specializes in respiratory therapeutics. | Biosyntia Biosyntia is a biotech company that specializes in synthetic biology and metabolic engineering. | LimmaTech Biologics LimmaTech Biologics is a biopharmaceutical company focused on the development and manufacture of pharmaceuticals. | ![]() Faraday Pharmaceuticals Faraday Pharmaceuticals is a company specializing in the use of elemental reducing agents to support the quality of life after acute, critical illness. | |
Founding Date | Founding Date 2009 | Founding Date 1996 | Founding Date 2012 | Founding Date 2015 | Founding Date 2014 |
Type | Type Private | Type Public | Type Private | Type Private | Type Private |
Tags | |||||
Locations | Locations South San Francisco, US HQ | Locations Allschwil, CH HQ | Locations København, DK HQ | Locations Schlieren, CH HQ | Locations Seattle, US HQ |
Employees | Employees 1 | Employees 50 | Employees 22 | Employees 53 | Employees 274% increase |
Funding | |||||
Latest funding round | Latest funding round $ 20m (over 6 years ago) | Latest funding round N/A | Latest funding round $ 4.7m (about 8 years ago) | Latest funding round N/A | Latest funding round $ 25m (over 6 years ago) |
Total funding raised | Total funding raised $ 20m | Total funding raised N/A | Total funding raised $ 6.6m | Total funding raised N/A | Total funding raised $ 88m |

Spexis (formerly known as Polyphor) is a bioengineering company that specializes in respiratory therapeutics.
View companyBiosyntia is a biotech company that specializes in synthetic biology and metabolic engineering.
View companyLimmaTech Biologics is a biopharmaceutical company focused on the development and manufacture of pharmaceuticals.
View company
Faraday Pharmaceuticals is a company specializing in the use of elemental reducing agents to support the quality of life after acute, critical illness.
View company